老年转移性尿路上皮癌患者使用维多汀的疗效和安全性：一项多中心回顾性研究。

IF 3 3区医学 Q3 GERIATRICS & GERONTOLOGY

Journal of geriatric oncology Pub Date : 2025-01-09 DOI:10.1016/j.jgo.2024.102183

Tetsuya Shindo , Kohei Hashimoto , Toshiki Kenuka , Shintaro Miyamoto , Yoshiki Hiyama , Fumimasa Fukuta , Yasuharu Kunishima , Manabu Okada , Masanori Matsukawa , Ryuichi Kato , Masaya Senda , Atsushi Wanifuchi , Shunsuke Sato , Ko Kobayashi , Toshiaki Tanaka , Naoya Masumori , on behalf of the Sapporo Medical University Urologic Oncology Consortium

{"title":"老年转移性尿路上皮癌患者使用维多汀的疗效和安全性：一项多中心回顾性研究。","authors":"Tetsuya Shindo , Kohei Hashimoto , Toshiki Kenuka , Shintaro Miyamoto , Yoshiki Hiyama , Fumimasa Fukuta , Yasuharu Kunishima , Manabu Okada , Masanori Matsukawa , Ryuichi Kato , Masaya Senda , Atsushi Wanifuchi , Shunsuke Sato , Ko Kobayashi , Toshiaki Tanaka , Naoya Masumori , on behalf of the Sapporo Medical University Urologic Oncology Consortium","doi":"10.1016/j.jgo.2024.102183","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to evaluate the efficacy and safety of enfortumab vedotin therapy for a cohort of older Japanese patients with metastatic urothelial carcinoma compared to younger patients.</div></div><div><h3>Materials and Methods</h3><div>We retrospectively evaluated patients with metastatic urothelial carcinoma treated with enfortumab vedotin and recruited between April 2019 and February 2023. Older patients were defined as being ≥75 years old. Efficacy was evaluated by comparing overall survival, progression-free survival, and objective response rates between groups. Adverse events and relative dose intensity were also compared. Moreover, the prognostic factor for overall survival in the entire cohort was evaluated using multivariate analysis.</div></div><div><h3>Results</h3><div>Of the 57 patients treated with enfortumab vedotin, 37 were younger and 20 were older, (median ages of 67.6 and 79.2, respectively). Median overall survival in older and younger patients was 407 and 365 days, respectively (<em>P</em> = 0.48). The objective response rate was 60.0 % and 54 % (<em>P</em> = 0.68) and median progression-free survival 228 and 223 days in older and younger patients, respectively (<em>P</em> = 0.76). Adverse events were equivalent between groups except for liver dysfunction, which frequently occurred in younger patients. The dose intensity for the older and younger patients did not differ (65.7 % vs. 63.5 %, <em>P</em> = 0.37, respectively). In multivariate analysis, neutrophil-to-lymphocyte ratio of 3 or more was the only risk factor for worse overall survival in the entire cohort (<em>P</em> = 0.04).</div></div><div><h3>Discussion</h3><div>Our data demonstrated that enfortumab vedotin therapy can benefit older patients with metastatic urothelial carcinoma equivalent to younger patients without compromising safety profiles.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102183"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study\",\"authors\":\"Tetsuya Shindo , Kohei Hashimoto , Toshiki Kenuka , Shintaro Miyamoto , Yoshiki Hiyama , Fumimasa Fukuta , Yasuharu Kunishima , Manabu Okada , Masanori Matsukawa , Ryuichi Kato , Masaya Senda , Atsushi Wanifuchi , Shunsuke Sato , Ko Kobayashi , Toshiaki Tanaka , Naoya Masumori , on behalf of the Sapporo Medical University Urologic Oncology Consortium\",\"doi\":\"10.1016/j.jgo.2024.102183\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>We aimed to evaluate the efficacy and safety of enfortumab vedotin therapy for a cohort of older Japanese patients with metastatic urothelial carcinoma compared to younger patients.</div></div><div><h3>Materials and Methods</h3><div>We retrospectively evaluated patients with metastatic urothelial carcinoma treated with enfortumab vedotin and recruited between April 2019 and February 2023. Older patients were defined as being ≥75 years old. Efficacy was evaluated by comparing overall survival, progression-free survival, and objective response rates between groups. Adverse events and relative dose intensity were also compared. Moreover, the prognostic factor for overall survival in the entire cohort was evaluated using multivariate analysis.</div></div><div><h3>Results</h3><div>Of the 57 patients treated with enfortumab vedotin, 37 were younger and 20 were older, (median ages of 67.6 and 79.2, respectively). Median overall survival in older and younger patients was 407 and 365 days, respectively (<em>P</em> = 0.48). The objective response rate was 60.0 % and 54 % (<em>P</em> = 0.68) and median progression-free survival 228 and 223 days in older and younger patients, respectively (<em>P</em> = 0.76). Adverse events were equivalent between groups except for liver dysfunction, which frequently occurred in younger patients. The dose intensity for the older and younger patients did not differ (65.7 % vs. 63.5 %, <em>P</em> = 0.37, respectively). In multivariate analysis, neutrophil-to-lymphocyte ratio of 3 or more was the only risk factor for worse overall survival in the entire cohort (<em>P</em> = 0.04).</div></div><div><h3>Discussion</h3><div>Our data demonstrated that enfortumab vedotin therapy can benefit older patients with metastatic urothelial carcinoma equivalent to younger patients without compromising safety profiles.</div></div>\",\"PeriodicalId\":15943,\"journal\":{\"name\":\"Journal of geriatric oncology\",\"volume\":\"16 2\",\"pages\":\"Article 102183\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-01-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of geriatric oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1879406824004569\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of geriatric oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879406824004569","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

内容简介我们旨在评估与年轻患者相比，恩福单抗韦多汀治疗日本老年转移性尿路上皮癌患者队列的有效性和安全性：我们对2019年4月至2023年2月期间招募的接受恩福单抗维多汀治疗的转移性尿路上皮癌患者进行了回顾性评估。老年患者定义为年龄≥75岁。疗效通过比较组间总生存期、无进展生存期和客观反应率进行评估。同时还比较了不良反应和相对剂量强度。此外，还通过多变量分析评估了整个组群总生存期的预后因素：结果：在接受恩福单抗维多汀治疗的57名患者中，37名患者年龄较小，20名患者年龄较大（中位年龄分别为67.6岁和79.2岁）。老年患者和年轻患者的中位总生存期分别为407天和365天（P=0.48）。老年患者和年轻患者的客观反应率分别为 60.0% 和 54%（P = 0.68），无进展生存期中位数分别为 228 天和 223 天（P = 0.76）。除肝功能异常常发生于年轻患者外，其他不良反应在各组之间相当。老年患者和年轻患者的剂量强度没有差异（分别为 65.7% 和 63.5%，P = 0.37）。在多变量分析中，中性粒细胞与淋巴细胞比值大于或等于3是整个队列中总生存率降低的唯一风险因素（P = 0.04）：我们的数据表明，恩福单抗维多汀疗法可使老年转移性尿路上皮癌患者受益，其受益程度与年轻患者相当，且不影响安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study

Introduction

We aimed to evaluate the efficacy and safety of enfortumab vedotin therapy for a cohort of older Japanese patients with metastatic urothelial carcinoma compared to younger patients.

Materials and Methods

We retrospectively evaluated patients with metastatic urothelial carcinoma treated with enfortumab vedotin and recruited between April 2019 and February 2023. Older patients were defined as being ≥75 years old. Efficacy was evaluated by comparing overall survival, progression-free survival, and objective response rates between groups. Adverse events and relative dose intensity were also compared. Moreover, the prognostic factor for overall survival in the entire cohort was evaluated using multivariate analysis.

Results

Of the 57 patients treated with enfortumab vedotin, 37 were younger and 20 were older, (median ages of 67.6 and 79.2, respectively). Median overall survival in older and younger patients was 407 and 365 days, respectively (P = 0.48). The objective response rate was 60.0 % and 54 % (P = 0.68) and median progression-free survival 228 and 223 days in older and younger patients, respectively (P = 0.76). Adverse events were equivalent between groups except for liver dysfunction, which frequently occurred in younger patients. The dose intensity for the older and younger patients did not differ (65.7 % vs. 63.5 %, P = 0.37, respectively). In multivariate analysis, neutrophil-to-lymphocyte ratio of 3 or more was the only risk factor for worse overall survival in the entire cohort (P = 0.04).

Discussion

Our data demonstrated that enfortumab vedotin therapy can benefit older patients with metastatic urothelial carcinoma equivalent to younger patients without compromising safety profiles.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of geriatric oncology ONCOLOGY-GERIATRICS & GERONTOLOGY

CiteScore

5.30

自引率

10.00%

发文量

379

审稿时长

80 days

期刊介绍： The Journal of Geriatric Oncology is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship issues of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. The journal welcomes the submission of manuscripts in the following categories: • Original research articles • Review articles • Clinical trials • Education and training articles • Short communications • Perspectives • Meeting reports • Letters to the Editor.